Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome
Public ClinicalTrials.gov record NCT00127881. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open Label, Dose Escalation, Followed by Open Label,Single Arm Clinical Trial of HuMax-CD4 in Patients With Mycosis Fungoides Type CTCL (Stage IB-IVB) or Sezary Syndrome Who Are Refractory or Intolerant to Targretin® (Bexarotene) and One Other Standard Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the efficacy of the drug, HuMax-CD4, in patients with mycosis fungoides(MF) and sezary syndrome who are intolerant to or do not respond to treatment with Targretin® and one other standard therapy.
Study identification
- NCT ID
- NCT00127881
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 76 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2005 (Type not available)
- Primary completion
- Feb 2014 (Estimated)
- Completion
- Not listed
- Last update posted
- Jul 26, 2012
Started 2005
United States locations
- U.S. sites
- 19
- U.S. states
- 16
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | — | — |
| Stanford University Medical Center | Stanford | California | 94305 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| H. Lee Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| The Emory Clinic | Atlanta | Georgia | 30322 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Tulane University Health Science Center | New Orleans | Louisiana | 70112 | — |
| Boston Medical Center | Boston | Massachusetts | 02118 | — |
| University of Michigan Medical Center | Ann Arbor | Michigan | 48109 | — |
| New York Medical Center | New York | New York | 10016 | — |
| Memorial Sloan Kettering | New York | New York | 10021 | — |
| SUNY Upstate Medical University | Syracuse | New York | 13210 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| University Hospital of Cleveland | Cleveland | Ohio | 44106 | — |
| Ohio State University | Columbus | Ohio | 43201 | — |
| Oregon Health & Science University | Portland | Oregon | 97239 | — |
| University of Pennsylvania Health System | Philadelphia | Pennsylvania | 19104 | — |
| Middle Tennessee Research Institute | Nashville | Tennessee | 37212-2637 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00127881, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 26, 2012 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00127881 live on ClinicalTrials.gov.